CStone Pharmaceuticals
Bio-pharmaceutical company.
Launch date
Employees
Market cap
€209m
Enterprise valuation
€129m (Public information from Sep 2024)
Share price
HKD1.52 2616.HK
Shanghai Shanghai (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.0b | 244m | 481m | 464m | 569m | 748m | 1.1b |
| % growth | - | (77 %) | 98 % | (4 %) | 23 % | 31 % | 45 % |
| EBITDA | (1.2b) | (1.8b) | (788m) | (476m) | (30.8m) | (187m) | 87.4m |
| % EBITDA margin | (116 %) | (751 %) | (164 %) | (103 %) | (5 %) | (25 %) | 8 % |
| Profit | (1.2b) | (1.9b) | (903m) | (367m) | (26.4m) | (194m) | 68.9m |
| % profit margin | (118 %) | (788 %) | (188 %) | (79 %) | (5 %) | (26 %) | 6 % |
| EV / revenue | 6.5x | 29.7x | 9.4x | 4.2x | 2.0x | 1.9x | 1.0x |
| EV / EBITDA | -5.6x | -4.0x | -5.8x | -4.1x | -37.9x | -7.5x | 12.1x |
| R&D budget | 1.4b | 1.3b | 614m | 528m | - | - | - |
| R&D % of revenue | 135 % | 535 % | 128 % | 114 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$150m | Series A | ||
$260m | Series B | ||
| N/A | $285m Valuation: $1.5b | IPO | |
| Total Funding | €373m | ||
Related Content
Recent News about CStone Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.